Tysabri lawsuit

The report concludes that the FDA must contemplate restrictions comparable to these employed on the MS drug Tysabri, which is extremely restricted and patients are necessary to be heavily monitored for signs of an usually-fatal brain infection recognized as progressive … Continue reading →